Ligand Pharmaceuticals (LGND) EBIT Growth (5y) (2015 - 2026)

Ligand Pharmaceuticals (LGND) EBIT Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Ligand Pharmaceuticals 6.05 Bn 5.27 Bn 48.45 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 29.79%
Dec 31, 2025 -9.55%
Sep 30, 2025 71.09%
Jun 30, 2025 3.53%
Mar 31, 2025 -63.15%
Dec 31, 2024 1.09%
Sep 30, 2024 21.15%
Jun 30, 2024 -35.84%
Mar 31, 2024 -67.52%
Dec 31, 2023 -16.01%
Sep 30, 2023 -33.33%
Jun 30, 2023 -15.19%
Mar 31, 2023 -17.44%
Dec 31, 2022 -22.06%
Sep 30, 2022 -5.64%
Jun 30, 2022 -7.82%
Mar 31, 2022 -26.90%
Dec 31, 2021 14.26%
Sep 30, 2021 23.50%
Jun 30, 2021 63.05%